
1. malar j. 2017 apr 4;16(1):139. doi: 10.1186/s12936-017-1771-6.

prevalence genetic variants g6pd deficiency among two malagasy populations
living plasmodium vivax-endemic areas.

howes re(1)(2), chan er(3), rakotomanga ta(4)(5), schulte s(6), gibson j(3),
zikursh m(6), franchard t(4)(5), ramiranirina b(4), ratsimbasoa a(4)(7),
zimmerman pa(8).

author information: 
(1)center global health diseases, case western reserve university,
cleveland, oh, usa. rosalind.howes@bdi.ox.ac.uk.
(2)nuffield department medicine, oxford big data institute, university of
oxford, oxford, uk. rosalind.howes@bdi.ox.ac.uk.
(3)institute computational biology, case western reserve university,
cleveland, oh, usa.
(4)national malaria control programme, ministry health, antananarivo,
madagascar.
(5)faculty science, university antananarivo, antananarivo, madagascar.
(6)center global health diseases, case western reserve university,
cleveland, oh, usa.
(7)university antananarivo, antananarivo, madagascar.
(8)center global health diseases, case western reserve university,
cleveland, oh, usa. paz@case.edu.

background: prevalence variants g6pd deficiency plasmodium
vivax-endemic zones madagascar remain unknown. admixed
african-austronesian origins malagasy population make probable a
heterogeneous mix genetic variants spectrum clinical severity will
be circulating. would implications widespread use p. vivax
radical cure therapy. two study populations p. vivax-endemic western
foothills region madagascar selected g6pd screening. the
qualitative fluorescent spot test g6pd genotyping used screen all
participants.
results: total 365 unrelated male volunteers tsiroanomandidy,
mandoto, miandrivazo districts madagascar screened 12.9% were
found phenotypically g6pd deficient. full gene sequencing 95 samples
identified 16 single nucleotide polymorphisms, integrated a
genotyping assay. genotyping (n = 291) found one individual diagnosed the
severe g6pd mediterranean c563t mutation, remaining g6pd deficient
samples mutations african origin, g6pd a- g6pd a.
conclusions: deployment p. vivax radical cure madagascar must be
considerate risks presented observed prevalence g6pdd
prevalence. potential morbidity associated cumulative episodes p.
vivax clinical relapses requires strategy increasing access safe radical
cure. observed dominance african g6pdd haplotypes surprising given 
known mixed african-austronesian origins malagasy population; more
widespread surveying g6pdd epidemiology across island would required to
characterize distribution g6pd haplotypes across madagascar.

doi: 10.1186/s12936-017-1771-6 
pmcid: pmc5381087
pmid: 28376871  [indexed medline]

